Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2023-05-17 Regulatory Filings
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-05-17 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 16, 2023, by TScan Therapeutics, Inc. The content describes the entry into a sales agreement for an 'at-the-market' equity offering program, detailing the terms of the sales agreement with Wedbush Securities Inc. It includes information about the issuance and sale of common stock, commission details, and legal opinions related to the offering. There are no financial statements or comprehensive financial performance data presented, nor is this an earnings release or management discussion. The document is an update on capital raising activities and financing arrangements. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing event, not merely an announcement or reference to a report.
2023-05-16 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a sales agreement for common stock offering. It includes detailed information about the offering, risk factors, use of proceeds, plan of distribution, and legal matters. The document is a formal offering document used to raise capital through the sale of shares. This type of document is classified as a Capital/Financing Update (CAP) because it provides updates on company fundraising and financing activities, specifically an at-the-market equity offering. It is not an annual report, earnings release, or any other report type, but a financing prospectus supplement.
2023-05-16 English
AW
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting the withdrawal of a pre-effective amendment to a registration statement on Form S-3. It references regulatory filings and does not contain financial data, earnings, or report content. The document is short (1744 characters) and is a formal regulatory communication about a filing withdrawal, not a financial report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-05-16 English
S-3/A
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 1 to a Form S-3 Registration Statement filed with the SEC. Form S-3 is a registration statement used by companies to register securities for public offering under the Securities Act of 1933. The text includes details about the registration, indemnification of directors and officers, expenses related to issuance and distribution, and undertakings related to the registration statement. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and offering. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual filing document itself.
2023-05-16 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter from TScan Therapeutics, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and discusses procedural matters related to the registration statement's effective date. The content is a regulatory communication about the registration process and does not contain financial data, report content, or detailed disclosures. It is a regulatory filing related to securities registration, not a financial report or announcement of voting results, management changes, or other categories. Given the nature and length of the document, it fits best under Regulatory Filings (RNS).
2023-05-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.